Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00003612. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized Phase II Trial of Paclitaxel, Carboplatin and rhuMAb Her-2 (Herceptin) as First-Line Chemotherapy in Patients With Metastatic Breast Cancer Who Overexpress Her-2
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of combining paclitaxel, carboplatin, and trastuzumab in treating women who have metastatic breast cancer that overexpresses HER2.
Study identification
- NCT ID
- NCT00003612
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 92 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 1999 (Actual)
- Primary completion
- Dec 2005 (Actual)
- Completion
- Mar 15, 2019 (Actual)
- Last update posted
- Oct 8, 2019
1999 – 2019
United States locations
- U.S. sites
- 24
- U.S. states
- 14
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| CCOP - Scottsdale Oncology Program | Scottsdale | Arizona | 85259-5404 | — |
| Mayo Clinic | Jacksonville | Florida | 32224 | — |
| CCOP - Illinois Oncology Research Association | Peoria | Illinois | 61602 | — |
| Carle Cancer Center | Urbana | Illinois | 61801 | — |
| CCOP - Carle Cancer Center | Urbana | Illinois | 61801 | — |
| CCOP - Cedar Rapids Oncology Project | Cedar Rapids | Iowa | 52403-1206 | — |
| CCOP - Iowa Oncology Research Association | Des Moines | Iowa | 50309-1016 | — |
| Siouxland Hematology-Oncology | Sioux City | Iowa | 51101-1733 | — |
| CCOP - Wichita | Wichita | Kansas | 67214-3882 | — |
| CCOP - Ochsner | New Orleans | Louisiana | 70121 | — |
| CCOP - Michigan Cancer Research Consortium | Ann Arbor | Michigan | 48106 | — |
| CCOP - Duluth | Duluth | Minnesota | 55805 | — |
| Mayo Clinic Cancer Center | Rochester | Minnesota | 55905 | — |
| CentraCare Health Plaza | Saint Cloud | Minnesota | 56303 | — |
| CCOP - Metro-Minnesota | Saint Louis Park | Minnesota | 55416 | — |
| CCOP - Missouri Valley Cancer Consortium | Omaha | Nebraska | 68106 | — |
| Medcenter One Health System | Bismarck | North Dakota | 58501-5505 | — |
| CCOP - Merit Care Hospital | Fargo | North Dakota | 58122 | — |
| Altru Cancer Center | Grand Forks | North Dakota | 58201 | — |
| CCOP - Toledo Community Hospital | Toledo | Ohio | 43623-3456 | — |
| CCOP - Geisinger Clinic and Medical Center | Danville | Pennsylvania | 17822-2001 | — |
| Rapid City Regional Hospital | Rapid City | South Dakota | 57709 | — |
| CCOP - Sioux Community Cancer Consortium | Sioux Falls | South Dakota | 57104 | — |
| CCOP - St. Vincent Hospital Cancer Center, Green Bay | Green Bay | Wisconsin | 54301 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00003612, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 8, 2019 · Synced Nov 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.